Advertisement

Advertisement

SABS Stock Latest News

SABS Upcoming Earnings Report: What to Expect?

Pre-EarningsSABS Upcoming Earnings Report: What to Expect?

SAB Biotherapeutics Launches Major Equity Financing Offering

PremiumCompany Announcements

SAB Biotherapeutics Launches Major Equity Financing Offering

5d ago

SAB Biotherapeutics 19.325M share Spot Secondary priced at $3.85

PremiumThe Fly

SAB Biotherapeutics 19.325M share Spot Secondary priced at $3.85

6d ago

SAB Biotherapeutics $75M Spot Secondary; price range $3.75-$4.07

PremiumThe Fly

SAB Biotherapeutics $75M Spot Secondary; price range $3.75-$4.07

7d ago

SAB Biotherapeutics announces common stock offering, no amount given

PremiumThe Fly

SAB Biotherapeutics announces common stock offering, no amount given

7d ago

SAB Biotherapeutics price target raised to $14 from $12 at Chardan

PremiumThe FlySAB Biotherapeutics price target raised to $14 from $12 at Chardan

14d ago

SAB Biotherapeutics Highlights New Phase 1 SAB-142 Data

Company Announcements

SAB Biotherapeutics Highlights New Phase 1 SAB-142 Data

14d ago

SAB Biotherapeutics announces additional Phase 1 data for SAB-142

The Fly

SAB Biotherapeutics announces additional Phase 1 data for SAB-142

14d ago

Analysts Predict Up to 400% Spike for These 2 ‘Strong Buy’ Penny Stocks

PremiumStock Analysis & Ideas

Analysts Predict Up to 400% Spike for These 2 ‘Strong Buy’ Penny Stocks

2M ago

SAB Biotherapeutics Updates SAB-142 Roadmap and Funding Outlook

PremiumCompany Announcements

SAB Biotherapeutics Updates SAB-142 Roadmap and Funding Outlook

2M ago

SAB Biotherapeutics Appoints New Independent Board Chair, Directors

PremiumCompany Announcements

SAB Biotherapeutics Appoints New Independent Board Chair, Directors

3M ago

SAB Biotherapeutics initiated with a Buy at UBS

PremiumThe Fly

SAB Biotherapeutics initiated with a Buy at UBS

3M ago

Aligos Therapeutics initiated with a Buy at UBS

PremiumThe FlyAligos Therapeutics initiated with a Buy at UBS

3M ago

SAB Biotherapeutics appoints David Zaccardelli as board chair

The Fly

SAB Biotherapeutics appoints David Zaccardelli as board chair

3M ago

SAB Biotherapeutics files $300M mixed securities shelf

The Fly

SAB Biotherapeutics files $300M mixed securities shelf

3M ago

SAB Biotherapeutics Launches New $75 Million ATM Program

PremiumCompany Announcements

SAB Biotherapeutics Launches New $75 Million ATM Program

3M ago

PremiumRatings

SAB Biotherapeutics: Favorable SAB-142 Safety Profile and De-Risked Phase 2b Design Underpin Buy Rating

3M ago

SAB Biotherapeutics initiated with a Buy at Guggenheim

PremiumThe Fly

SAB Biotherapeutics initiated with a Buy at Guggenheim

3M ago

SAB Biotherapeutics announces first patient dosed in SAFEGUARD trial

PremiumThe Fly

SAB Biotherapeutics announces first patient dosed in SAFEGUARD trial

3M ago

SAB Biotherapeutics Phase 1 trial of SAB-142 met primary endpoint

PremiumThe FlySAB Biotherapeutics Phase 1 trial of SAB-142 met primary endpoint

3M ago

Eleven new option listings and two option delistings on December 8th

The Fly

Eleven new option listings and two option delistings on December 8th

4M ago

SAB Biotherapeutics to present data on progress in development of SAB-142

The Fly

SAB Biotherapeutics to present data on progress in development of SAB-142

4M ago

Trending

S&P 500

―

Dow Jones

―

Nasdaq 100

―

More Trending Stocks >